GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nevro Corp (NYSE:NVRO) » Definitions » Forward PE Ratio

Nevro (NVRO) Forward PE Ratio : 0.00 (As of May. 25, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Nevro Forward PE Ratio?

Nevro's Forward PE Ratio for today is 0.00.

Nevro's PE Ratio without NRI for today is 0.00.

Nevro's PE Ratio for today is 0.00.


Nevro Forward PE Ratio Historical Data

The historical data trend for Nevro's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nevro Forward PE Ratio Chart

Nevro Annual Data
Trend 2017-11
Forward PE Ratio
666.67

Nevro Quarterly Data
Forward PE Ratio

Competitive Comparison of Nevro's Forward PE Ratio

For the Medical Devices subindustry, Nevro's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nevro's Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nevro's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Nevro's Forward PE Ratio falls into.



Nevro Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Nevro  (NYSE:NVRO) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Nevro Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Nevro's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nevro (NVRO) Business Description

Traded in Other Exchanges
Address
1800 Bridge Parkway, Redwood City, CA, USA, 94065
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
Executives
Greg Siller officer: Chief Commercial Officer C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Shawn Mccormick director 9600-54TH AVENUE NORTH, SUITE 100, PLYMOUTH MN 55441
Kevin R Thornal officer: President & CEO 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Sridhar Kosaraju director 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Elizabeth H Weatherman director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Richard B. Carter officer: Chief Accounting Officer C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Kashif Rashid officer: General Counsel C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
D Keith Grossman director, officer: President & CEO
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
Michael F Demane director, officer: Chief Executive Officer MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Niamh Louise Pellegrini officer: Chief Commercial Officer C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Brad Vale director C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Susan E Siegel director 3000 SAND HILL ROAD, BLDG 3 STE 290, MENLO PARK CA 94025
Roderick H. Macleod officer: Chief Financial Officer C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Patrick Schmitz officer: Vice President, Operations C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065